2014 Communication Documentation 
RX Note
JUNE 11, 2025
In 2014, the Joint Commission for Pharmacy Practitioners (JCPP) - representing 11 national pharmacy organizations - endorsed a framework for providing clinically oriented patient care services called the Pharmacist's Patient Care Process.
Eye on FDA
AUGUST 2, 2022
There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 15, 2021
536/2014, due to come into force in February next year. That’s why the GLSP document, which has been included in EudraLex Volume 10, is just as applicable in other markets, including the UK and US, as they are in the EU. “We New lay summary guidelines walk sponsors through their obligations under EU regulation No.
ID Stewardship
DECEMBER 13, 2024
It may be derived from work completed inthe microbiology lab, unitsdispensed from the pharmacy, administrations performed by nurses, expenditures produced from drug purchases, documentation within any area of the electronic medical record, extraction from supplemental tools or data warehouses, and so much more.
Pulses
SEPTEMBER 26, 2023
This shift highlights the significance of effective communication, teamwork, and adaptability. Despite the challenge of quantifying these skills, their influence on a student’s ability to cultivate professional relationships, effectively communicate, and collaborate in a team cannot be overstated. teacher), entertainment (ex.
Eye on FDA
JULY 7, 2020
In the now distant past, enforcement from this office, then called the Division of Drug Marketing, Advertising, and Communications (DDMAC) and later re-named OPDP, was robust, with the office issuing scores of letters a year (156 were issued in 1998). One of them was about the appropriate use of links.
Pharmaceutical Technology
JANUARY 6, 2023
The agreement outlined that Par would keep its generic equivalent off the market for as many as two years, delaying the generic launch till September 30, 2014. This class-action litigation specifically focused on a 2011 licensing agreement between the two companies. These actions allegedly led to the extension of Novartis’ patents.
Expert insights. Personalized for you.
52 
Let's personalize your content